Financial News Feed

Stronger Sell Today AIMT ranks #4133 as SELL CANDIDATE #4133 Weaker Sell

AIMT stock forecast Aimmune Therapeutics

AIMT stock forecast

No summary available....

Read more

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q1 2019 Earnings Conference Call May 08, 2019 4:30 PM ET Company Participants Eric Bjerkholt - Chief Financial Officer...

Read more

AIMT earnings call for the period ending March 31, 2019....

Read more

Aimmune Therapeutics beats by $0.10
08:06pm, Wednesday, 08'th May 2019
No summary available....

Read more

Aimmune Therapeutics Q1 Earnings Preview
09:35pm, Tuesday, 07'th May 2019
Aimmune Therapeutics (NASDAQ:AIMT) is scheduled to announce Q1 earnings results on Tuesday, May 7th, after market close. The consensus EPS Estimate is -$0....

Read more

Small Cap Growth Strategy Q1 '19 Commentary
12:15pm, Tuesday, 30'th Apr 2019
No summary available....

Read more

Here we will take a look into some valuation metrics for Aimmune Therapeutics, Inc. NasdaqGS:AIMT shares. Price-To-Cash-Flow-Ratio is a term that indicates the degree of cash flow valuation of the ent...

Read more

Both Neurotrope Inc. (NASDAQ:NTRP) and Aimmune Therapeutics Inc. (NASDAQ:AIMT) are each other’s competitor in the Biotechnology industry. Thus the compare of their profitability, analyst recommendat...

Read more

This is a contrast between Akcea Therapeutics Inc. (NASDAQ:AKCA) and Aimmune Therapeutics Inc. (NASDAQ:AIMT) based on their risk, analyst recommendations, profitability, dividends, institutional owner...

Read more

MorphoSys AG (NASDAQ:MOR) and Aimmune Therapeutics Inc. (NASDAQ:AIMT), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst ...

Read more

Both Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Aimmune Therapeutics Inc. (NASDAQ:AIMT) are each other’s competitor in the Biotechnology industry. Thus the compare of their profitability, analys...

Read more

Using projections from 7 individual sell-side analysts polled by Zacks Research, Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has a current quarter EPS consensus estimate of -0.92. Going back to the previ...

Read more

Investors may be looking at all the different factors that come into play when searching for those next stocks to add to the portfolio. Maybe there are some names that have been on the radar, but the ...

Read more

We will be comparing the differences between Aimmune Therapeutics Inc. (NASDAQ:AIMT) and ERYTECH Pharma S.A. (NASDAQ:ERYP) as far as profitability,...

Read more

Both Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) and Aimmune Therapeutics Inc. (NASDAQ:AIMT) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, prof...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank